AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00613730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Intravenous administration
Study NCT04125914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo exercise
Study NCT04125914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive text messages
Study NCT04125914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Join Facebook page
Study NCT02819518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion
Study NCT02819518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion
Study NCT02819518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT02819518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT02819518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion
Study NCT02819518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study NCT02819518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT02819518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT02819518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normale Saline Solution
Description: IV infusion
Study NCT03793868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral tablet
Study NCT03254732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
Study NCT03254732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
Study NCT03793868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (not drug)
Study NCT01580514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide BYETTA® (Amylin-Lilly)
Description: After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days.
Study NCT01580514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days.
Study NCT04125914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01756300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celsius® ThermoCool® RD
Description: The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
Study NCT03230253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential training
Description: The participant will cycle on a stationary bike for 30 minutes, which includes a 3-min warm-up phase followed by the aerobic training components (25 minutes), then a 2-min cool-down phase. The target heart rate during the aerobic training phase will be 40 to 70% of maximal heart rate (HRmax). After cycling, the participant will engage in a 30-minute of computer-based cognitive training program using BrainHQ (Posit Science Inc., San Francisco, CA, USA). The following are the areas of training: visuospatial processing, attention, memory, language, and logical thinking.
Study NCT03230253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual training
Description: The dual-task training group will cycling concurrently with the computer-based cognitive training. The training principle of cycling and cognitive training is similar to the SEQ group; however, the training intensity will be adjusted according to each participant's ability.
Study NCT03230253 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control training
Description: The control participants will receive 60 minutes of health-related rehabilitation programs which involves non-aerobic physical exercise (e.g., muscle stretching, range of motion exercises, relaxation techniques) and unstructured cognitive related rehabilitation programs (e.g., watch health-related videos or read newspapers or magazines and then answer the content-related questions raised by the therapist).
Study NCT03334708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:~Patients and controls weighing 50kg or more~* For draw amounts up to 50mL, there is no required hemoglobin threshold.~* For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period.~Patients and controls weighing \< 50kg~* For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time.
Study NCT03334708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor Tissue Collection
Description: Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
Study NCT04125914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone coaching
Study NCT03770130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine, a selective α2-adrenoceptor agonist which is widely used as an adjuvant to general anaesthesia
Study NCT03770130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline, a kind of crystalloid widely used in clinical treatment
Study NCT01562132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine and fluconazole
Description: Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
Study NCT01562132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
Study NCT03969706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 MG
Description: Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
Study NCT04592276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS128
Description: Participants took two capsules with PS128 after dinner for 30 days.
Study NCT04592276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants took two capsules without PS128 after dinner for 30 days.
Study NCT03334708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cyst Fluid
Description: Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
Study NCT02971787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Day 1-21: 2 capsules per day
Study NCT02971787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt
Description: Day 8-21: 10 tablets à 600 mg per day
Study NCT03856034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscopy
Description: Patients will receive fetoscopic repair of myelomeningocele. Patients with an anterior placenta will undergo the laparotomy with uterine exteriorization approach. Patients with a posterior placenta will undergo the percutaneous approach (or, if patient prefers, the laparotomy with uterine exteriorization approach).
Study NCT03632694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching and Tech Support
Description: Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. Additionally, this arm receives health coaching to provide encouragement and further motivate and help study participants to modify their sedentary behavior.
Study NCT03632694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tech Support Only
Description: Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. However, there is no additional health coaching.
Study NCT02712294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Study NCT02876133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narrow band imaging withdrawal
Description: colonoscope withdrawal and mucosal inspection performed under narrow band imaging
Study NCT02876133 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: white light withdrawal
Description: colonoscope withdrawal and mucosal inspection performed under white light imaging
Study NCT03864458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7791
Description: oral administration
Study NCT02484573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol
Study NCT04269200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: Olaparib tablets
Study NCT04269200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab by intravenous infusion
Study NCT04269200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: durvalumab placebo
Description: Matching placebo for intravenous infusion
Study NCT04269200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olaparib placebo
Description: Placebo tablets to match olaparib
Study NCT04269200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib placebo
Description: Placebo tablets to match olaparib
Study NCT04269200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Standard of care chemotherapy
Study NCT04269200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Standard of care chemotherapy
Study NCT01599832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO
Study NCT01599832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01599832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo dynamic contrast-enhanced magnetic resonance imaging
Study NCT01599832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study NCT01721707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost+Brinzolamide combination
Description: 1 drop in each eye, 1x/day, at 9PM
Study NCT01721707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: 1 drop in each eye, 1x/day, at 9PM
Study NCT04269200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Standard of care chemotherapy
Study NCT04269200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Standard of care chemotherapy
Study NCT02459652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
Study NCT02459652 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy is delivered with >6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
Study NCT04595604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trimodal rehabilitation + ERAS
Description: Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
Study NCT04595604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERAS + nutritional prehabilitation
Description: Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
Study NCT00667602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 (two doses)
Description: Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
Study NCT00667602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenC
Description: One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
Study NCT00667602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV7
Description: One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
Study NCT00667602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV7
Description: One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
Study NCT00667602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV-HepB-Hib
Description: One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
Study NCT00667602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-IPV-HepB-Hib
Description: One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
Study NCT00667602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 (one dose)
Description: One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
Study NCT02698059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNAP® Sleep Therapy System (iNAP)
Description: The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
Study NCT03136302 — intervention group
Intervention type: PROCEDURE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation
Study NCT02452593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tibial stimulation and pelvic floor exercises
Description: A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks
Study NCT03165695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first
Study NCT03165695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
Study NCT02442531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CriPec® docetaxel
Description: -3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops
Study NCT02800746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.
Study NCT02800746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline 100 ml is intravenously administered on 7-10 day before surgery
Study NCT01946646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1-CCRT
Study NCT03376412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: A maximum of 60 consecutive non-dominant eyes will be implanted with the Raindrop Near Vision Inlay.
Study NCT01893099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
Study NCT01893099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radioembolization with SIR-Spheres® (Yttrium Microspheres)
Study NCT01270061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing
Description: HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.
Study NCT01270061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Health Screen
Description: A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
Study NCT01812772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double J-stent with a long tether
Description: Patients will receive a double-J stent placement with a long tether following ureteroscopy.
Study NCT01812772 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double J-stent without a long tether
Description: Patients will receive a double-J stent placement without a long tether following ureteroscopy.
Study NCT03864458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study NCT03328520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WILD 5 Wellness Intervention
Description: Behaviors in 6 areas of wellness: Sleep, Social Connectedness, Exercise, Nutrition, Mindfulness and HERO (Happiness, Enthusiasm, Resilience, Optimism)
Study NCT03318913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5g of the sucralose administered as white plastic capsules
Study NCT03318913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fish protein hydrolysates
Description: 5g of the FPH dissolving in 100 mL of water
Study NCT01726257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nellix System
Description: Subjects in this study will receive a Nellix Endovascular Sealing System as part of their intervention.
Study NCT00781079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consumer Provider
Description: Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
Study NCT00879684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVX-060
Description: Weekly, intravenous dose
Study NCT04993417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery technique along with EMS
Description: All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. The patients were mentioned to play out the emotional facial appearances for non-verbal correspondence i-e pleasure, misery, interest, appall, dread, irritation and shock. Patients were then requestedto envision himself winking, for instance, envisioning himself in a wonderful and natural social setting, at that point the patient cognitively addresses, with his eyes shut, the movement of decaying the recognized central issues, without creating any specific movement.